SCYNEXIS, Inc. (SCYX)

NASDAQ: SCYX · IEX Real-Time Price · USD
2.59
+0.06 (2.37%)
Oct 7, 2022 4:00 PM EDT - Market closed
2.37%
Market Cap 84.57M
Revenue (ttm) 3.12M
Net Income (ttm) -48.64M
Shares Out 32.65M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,776
Open 2.55
Previous Close 2.53
Day's Range 2.47 - 2.59
52-Week Range 1.70 - 8.10
Beta 1.99
Analysts Buy
Price Target 18.80 (+625.9%)
Earnings Date Nov 8, 2022

About SCYX

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the p... [Read more...]

Industry Pharmaceuticals
IPO Date May 2, 2014
Employees 56
Stock Exchange NASDAQ
Ticker Symbol SCYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SCYX stock is "Buy." The 12-month stock price forecast is 18.8, which is an increase of 625.87% from the latest price.

Price Target
$18.8
(625.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SCYNEXIS to Participate in Upcoming September Investor Conferences

JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

4 weeks ago - GlobeNewsWire

SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI ...

JERSEY CITY, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

4 weeks ago - GlobeNewsWire

SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022

JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

1 month ago - GlobeNewsWire

Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 month ago - GlobeNewsWire

SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurr...

JERSEY CITY, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

2 months ago - GlobeNewsWire

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the S...

JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

2 months ago - GlobeNewsWire

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Comp...

JERSEY CITY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 months ago - GlobeNewsWire

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

4 months ago - GlobeNewsWire

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

4 months ago - GlobeNewsWire

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Pha...

JERSEY CITY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

4 months ago - GlobeNewsWire

SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study...

Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 years Product theater presentation will be held on...

5 months ago - GlobeNewsWire

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Inclu...

JERSEY CITY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

5 months ago - GlobeNewsWire

SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warra...

5 months ago - GlobeNewsWire

Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections

SCYNEXIS Inc (NASDAQ: SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who ar...

5 months ago - Benzinga

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The...

5 months ago - GlobeNewsWire

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potenc...

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

5 months ago - GlobeNewsWire

Why Scynexis Shares Are Falling During Thursday's After-Hours Session

SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the offering was not disclosed.

5 months ago - Benzinga

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to pu...

5 months ago - GlobeNewsWire

SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of...

Data from studies evaluating ibrexafungerp in serious fungal infections will be presented Data from studies evaluating ibrexafungerp in serious fungal infections will be presented

5 months ago - GlobeNewsWire

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providin...

Advanced first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for approximately 55 percent of commercially-insured U.S. patients Advanced first-in-class, one-day oral antifungal ...

5 months ago - GlobeNewsWire

SCYNEXIS to Participate in Upcoming April Women's Health Medical Conferences

JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

6 months ago - GlobeNewsWire

Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of -47.89% and 53.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research